Orion - Company Announcement

Orion Corporation issues a EUR 150 million domestic bond on 11 June 2013

ORION CORPORATION        STOCK EXCHANGE RELEASE 4 JUNE 2013 at 3.45 p.m. EEST



Orion Corporation has resolved to issue a EUR 150 million fixed rate unsecured
bond. The funds will be used for general corporate purposes. The bond matures
in six (6) years and pays a coupon of 2.75 percent. The bond will be applied to
be listed on NASDAQ OMX Helsinki Ltd.

Pohjola Markets acts as lead manager for the transaction.




Orion Corporation





 Timo Lappalainen    Jari Karlson
 President and CEO   CFO







Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

Disclaimer

The  information contained in this release shall not constitute an offer to sell
securities of Orion Corporation in any jurisdiction. In particular, this release
does  not  constitute  an  offer  to  sell  securities in the United States. Any
securities  referred to herein have not been,  and will not be, registered under
the  U.S. Securities Act of 1933, as amended,  and may not be offered, exercised
or sold in the United States absent registration or an applicable exemption from
registration requirements.


[HUG#1706923]